A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Melanoma Clinical Trial

Official title:

An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05091346
• Other study ID #: E7386-G000-201
• Secondary ID: 2021-001568-10KE
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 27, 2021
• Est. completion date: September 30, 2025

Study information

• Verified date: June 2023
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab.

The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 89
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Male or female, age >=18 years at the time of informed consent

2. Have a histologically or cytologically-documented, advanced (metastatic and/or unresectable) selected solid tumor for which prior standard systemic therapy has failed. Selected tumor types: melanoma (excluding uveal melanoma), CRC, HCC

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

4. Must have disease progression on current or since the last anticancer treatment

5. At least one measurable lesion by computer tomography (CT) or magnetic imaging resonance (MRI) based on RECIST 1.1

6. Adequate organ function and serum mineral level per blood work as confirmed by the investigator

1. Calcium (albumin-corrected) within normal range

2. Potassium within normal reference range

3. Magnesium less than or equal to (>=) 1.2 milligram per deciliter (mg/dL) or 0.5 millimoles per litre (mmol/L).

7. Melanoma cohort (Phase 2), participants must have:

• Unresectable Stage III or Stage IV melanoma, not amenable to local therapy.

• Received only 1 or, if BRAF mut +ve, 2 lines of therapies locally advanced or metastatic setting prior to study enrolment. Note: Adjuvant anti-PD-1/PD-L1 mAb/ BRAF inhibitor treatment will be counted as prior line of treatment if relapse occurred during active treatment or within 12 weeks of treatment discontinuation.

8. CRC cohort (Phase 2), participants must have received at least 2 prior systemic therapies in adjuvant and/or metastatic setting (not exceeding 4 lines of therapies in the metastatic setting, progressed on at least 1 prior regimen in the metastatic setting or could not tolerate standard treatment)

9. Participants with HCC cohort (Phase 2) must have:

• Stage B (not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment) or stage C based on Barcelona Clinic Liver Cancer [BCLC] staging System and Child-Pugh class A only.

• Have received only 1 prior line of systemic therapy in the locally advanced or metastatic setting, and must have progressed on treatment with an anti-PD-1/L1 monoclonal antibodies (mAb) administered either as monotherapy, or in combination

10. Must agree to take Vitamin D continuous supplementation as per local institutional guideline/ investigator's clinical discretion if their 25-hydroxyvitamin D levels are less than 10 nanogram per milliliter (ng/mL).

11. Triplet treatment cohorts only: Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP <=150/90 millimeter of mercury (mmHg) at Screening/Baseline and no change in antihypertensive medications within 1 week before starting treatment in this study.

Exclusion Criteria

1. Have present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to study drug administration. The participant can receive diuretic drugs as needed per the treating physician. Consult with the sponsor if the participant has more than trivial/trace fluid accumulation.

2. Prior treatment with E7386 or prior therapy with anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (example, CTLA-4, OX 40, CD137) that was discontinued due to a Grade 3 or higher immune-related (ir)AE

3. Participants with central nervous system (CNS) metastases are not eligible unless they are previously treated are radiologically stable, that is, without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), and are clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment

4. Any active infection requiring systemic treatment

5. Have severe hypersensitivity to study drugs and/or any of its excipients

6. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.

7. Have an active autoimmune disease that has required systemic treatment in the past 2 years

8. Have a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis

9. Any bone disease/conditions as follows:

• Osteoporosis with T-score <-2.5 by DXA scan

• Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia

• Symptomatic hypercalcemia requiring bisphosphonate therapy

• History of any fracture within 6 months prior to starting study drug

• History of symptomatic vertebral fragility fracture or any fragility fracture

• Moderate or severe morphometric vertebral fracture at baseline.

• Any condition requiring orthopedic intervention.

• Bone metastases not being treated with a bisphosphonate or denosumab

10. Active viral hepatitis (B or C) as demonstrated by positive serology for participants with melanoma and CRC. Dual active hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection at study entry for participants with HCC

11. Known to be human immunodeficiency virus (HIV) positive

12. Received blood/platelet transfusion or G-CSF within 4 weeks before study entry

13. For Melanoma only, participants with ocular melanoma are excluded. Note: Participants with mucosal melanoma will not exceed 20% of the enrolled participants in melanoma cohort in Phase 2.

14. For CRC only, participants are excluded if:

• have a tumor that is microsatellite instability high (MSI H)/ DNA mismatch repair-deficient (dMMR) positive

15. For HCC only, participants are excluded if:

• Clear invasion to bile duct

• Have had esophageal or gastric variceal bleeding within the last 6 months. Participants in triplet treatment cohorts will be screened for esophageal or gastric varices unless such screening has been performed in the past 3 months before first dose of treatment. If varices are present, they should be treated according to institutional standards before starting study intervention; esophageal or gastric varices that require interventional treatment within 28 days prior to first dose of study drug are excluded

• History of hepatic encephalopathy within 6 months prior to starting study drug unresponsive to therapy within 3 days. Participants on rifaximin or lactulose during screening to control their hepatic encephalopathy are not allowed

16. For participants in the triplet treatment cohorts only:

• Proteinuria greater than (>) 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein >=1 gram per 24 hours (g/24 hours) will be ineligible

• Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring (example, warfarin or similar agents). Treatment with low molecular weight heparin and factor X inhibitors is permitted

• Clinically significant hemoptysis from any source or tumor bleeding within 3 weeks prior to the first dose of study drug

• Pre-existing >=Grade 3 gastrointestinal or non-gastrointestinal fistula

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Colorectal Neoplasms
• Melanoma

Intervention

Drug:
• E7386
E7386 tablet.
• Pembrolizumab
Pembrolizumab IV infusion.
• Lenvatinib
Lenvatinib capsule.

Locations

Country	Name	City	State
Japan	Chiba University Hospital	Chiba-shi
Japan	National Cancer Center Hospital	Chuo-ku
Japan	Kurume University Hospital	Fukuoka
Japan	National Cancer Center Hospital East	Kashiwa
Japan	Kindai University Hospital	Osaka
Japan	Osaka Metropolitan University Hospital	Osaka
Japan	Sapporo-Kosei General Hospital	Sapporo shi
Japan	Shizuoka Cancer Center Hospital	Shizouka
Japan	Toranomon Hospital	Tokyo
Spain	Hospital Universitario de Badajoz	Badajoz
Spain	Hospital Clinic de Barcelona	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Clínico San Carlos	Madrid	Calle Profesor Martín Lagos
Spain	Hospital General Universitario Gregorio Maranon	Madrid
Spain	Hospital Universitario de la Paz	Madrid
Spain	Hospital Regional Universitario de Malaga	Malaga	Avenida Carolos Haya S/n
Spain	Clínica Universidad de Navarra	Pamplona	Navarra
Spain	Consorcio Hospital General Universitario de Valencia	Valencia
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Imperial College London	London
United Kingdom	Royal Free Hospital NHS Foundation Trust	London
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	The Royal Marsden NHS Foundation Trust - The Royal Marsden Hospital	Sutton	Surrey
United States	Emory University	Atlanta	Georgia
United States	Barbara Ann Karmanos Cancer Center	Detroit	Michigan
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	University of California, Los Angeles	Los Angeles	California
United States	Sarah Cannon Cancer Care in Nashville	Nashville	Tennessee
United States	Rutgers cancer Institute of NJ	New Brunswick	New Jersey
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	University of California, Irvine Health	Orange	California
United States	Providence Medical Center	Portland	Oregon
United States	SCRI Florida Cancer Specialists East	West Palm Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Eisai Inc.	Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Japan,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs)	DLTs are any pre-specified toxicities occurring during Cycle 1, based on investigator assessment as related to study drug. All adverse events (AEs) of the specified grades should count as DLTs except those that are clearly and incontrovertibly due to disease progression or extraneous causes. DLTs will be assessed to determine the RP2D of E7386 in combination with pembrolizumab. All toxicity will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.	Cycle 1 (Cycle length is equal to [=] 21 days)
Primary	Phase 1b Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)		From date of first dose of study drug up to 30 days after last administration of study drug (approximately up to 3 years 11 months)
Primary	Phase 2 Part: Objective Response Rate (ORR)	ORR is defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	From first dose of study drug until progressive disease (PD) or death, development of unacceptable toxicity, withdrawal of consent, or study termination (up to approximately 3 years 11 months)
Secondary	Phase 1b Part: Best of Response (BOR)	BOR is defined as CR, PR, stable disease (SD), PD, and not evaluable (NE), where SD has to be achieved at greater than equal to (>=) 5 weeks after the first dose per RECIST version 1.1.	From first dose of study drug until PD or death, development of unacceptable toxicity, withdrawal of consent, or study termination (up to approximately 3 years 11 months)
Secondary	Duration of Response (DOR)	DOR is defined as the time from the first documentation of CR or PR to the first documentation of disease progression or death due to any causes, whichever occurs first in participants with confirmed CR or PR as per RECIST version 1.1.	From the date of first documented CR or PR until first documentation of recurrent or progressive disease or death due to any causes (up to approximately 3 years 11 months)
Secondary	Disease Control Rate (DCR)	DCR is defined as the percentage of participants with BOR of confirmed CR, PR, or SD after >=5 weeks from first dose per RECIST version 1.1.	From first dose of study drug until PD or death, development of unacceptable toxicity, withdrawal of consent, or study termination (up to approximately 3 years 11 months)
Secondary	Clinical Benefit Rate (CBR)	CBR is defined as the percentage of participants who have a BOR of confirmed CR, PR, or durable SD (duration of SD >=23 weeks) per RECIST 1.1.	From first dose of study drug until PD or death, development of unacceptable toxicity, withdrawal of consent, or study termination (up to approximately 3 years 11 months)
Secondary	Phase 2 Part: Number of Participants With TEAEs and Treatment-related Adverse Events for E7386 in Combination With Pembrolizumab and E7386 in Combination With Pembrolizumab Plus Lenvatinib		From date of first dose of study drug up to 30 days after last administration of study drug (approximately up to 3 years 11 months)
Secondary	Phase 2 Part: Number of Participants With DLTs for E7386 in Combination With Pembrolizumab Plus Lenvatinib	DLTs are any pre-specified toxicities occurring during Cycle 1, based on investigator assessment as related to study drug. All AEs of the specified grades should count as DLTs except those that are clearly and incontrovertibly due to disease progression or extraneous causes. All toxicity will be graded using NCI CTCAE version 5.0.	Cycle 1 (Cycle length = 21 days)
Secondary	Phase 1b Part, Cmax: Maximum Observed Plasma Concentration for E7386 When Co-administered With Pembrolizumab		Cycle 1 Days 1 and 8: 0-12 hours post-dose (Cycle length = 21 days)
Secondary	Phase 1b Part, Tmax: Time to Reach the Maximum Plasma Concentration for E7386 When Co-administered With Pembrolizumab		Cycle 1 Days 1 and 8: 0-12 hours post-dose (Cycle length = 21 days)
Secondary	Phase 1b Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386 When Co-administered With Pembrolizumab		Cycle 1 Days 1 and 8: 0-12 hours post-dose (Cycle length = 21 days)
Secondary	Phase 2 Part: Apparent Clearance for E7386 When Co-administered With Lenvatinib and Pembrolizumab		Cycle 1 Day 1: 0.5-8 hours post-dose; Cycle 1 Day 8: 0-8 hours post-dose (Cycle length = 21 days)
Secondary	Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab		Cycle 1 Day 1: 0.5-8 hours post-dose; Cycle 1 Day 8: 0-8 hours post-dose (Cycle length = 21 days)